KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Cash (2018 - 2025)

Historic Change in Cash for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $6.4 million.

  • Esperion Therapeutics' Change in Cash rose 11432.26% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.3 million, marking a year-over-year decrease of 27490.97%. This contributed to the annual value of $62.5 million for FY2024, which is 24699.6% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Change in Cash of $6.4 million as of Q3 2025, which was up 11432.26% from -$28.6 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Change in Cash registered a high of $144.4 million during Q1 2024, and its lowest value of -$87.0 million during Q1 2021.
  • For the 5-year period, Esperion Therapeutics' Change in Cash averaged around -$11.2 million, with its median value being -$27.4 million (2022).
  • As far as peak fluctuations go, Esperion Therapeutics' Change in Cash plummeted by 229919.81% in 2022, and later surged by 61692.99% in 2024.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Change in Cash stood at $105.2 million in 2021, then plummeted by 180.43% to -$84.6 million in 2022, then surged by 61.49% to -$32.6 million in 2023, then skyrocketed by 100.14% to $44000.0 in 2024, then skyrocketed by 14413.64% to $6.4 million in 2025.
  • Its Change in Cash stands at $6.4 million for Q3 2025, versus -$28.6 million for Q2 2025 and -$30.1 million for Q1 2025.